DeepMind Talent Exodus Hits Alphabet: Nobel Winner John Jumper Joins Anthropic
Another major exit follows Noam Shazeer’s move to OpenAI.
Already have an account? Sign in.
Another major exit follows Noam Shazeer’s move to OpenAI.
Phase 2 data showed 77% seizure reduction and sustained benefits up to 1 year.
Entera Bio receives positive FDA feedback on its pivotal Phase 3 trial design for EB613, the potential first once-daily oral tablet to stimulate bone formation in postmenopausal women with osteoporosis.
Achieve Life Sciences received an FDA Complete Response Letter for its cytisinicline NDA due to manufacturing issues at a former facility. No efficacy or safety deficiencies were identified.